Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.

about

Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.

P2860

Q47339574-A3469640-74FF-4E8E-832A-A1CDDCAB8823 Q54979176-338D5328-DB2A-4754-B1A4-8BA2A55160DB

P2860

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.

Item

http://www.wikidata.org/entity/Q39472878

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@en

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@nl

type

Item

label

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@en

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@nl

prefLabel

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@en

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@nl

P1476

Sorafenib inhibits cell growth ...... ty of glioblastoma cell lines.

@en

P2093

Cordula Petersen

http://www.w3.org/2001/XMLSchema#string

Ekkehard Dikomey

http://www.w3.org/2001/XMLSchema#string

Justus Müller-Goebel

http://www.w3.org/2001/XMLSchema#string

Kai Rothkamm

http://www.w3.org/2001/XMLSchema#string

Malte Kriegs

http://www.w3.org/2001/XMLSchema#string

Matthias Riedel

http://www.w3.org/2001/XMLSchema#string

Nina Struve

http://www.w3.org/2001/XMLSchema#string

Sabrina Köcher

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.

Genetic alterations and signaling pathways in the evolution of gliomas.

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Pathway inhibition: emerging molecular targets for treating glioblastoma.

P304

61988-61995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.11328

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27542273

http://www.w3.org/2001/XMLSchema#string

P932

5308705

http://www.w3.org/2001/XMLSchema#string

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.

about

P2860

P2860

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932